La dysfonction d'organe au début de la grossesse influe sur la sélection systémique de la MF/Sézary : FVEF <50% (g...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | RF-MF-SEZARY-ORGAN-DYSFUNCTION |
|---|---|
| Type | Signal d’alerte |
| État | reviewed 2026-04-27 | pending_clinical_signoff |
| Maladies | DIS-MF-SEZARY |
| Sources | SRC-ESMO-CTCL-2024 SRC-NCCN-BCELL-2025 |
Origine du drapeau rouge
| Définition | Baseline organ dysfunction influencing MF/Sézary systemic-therapy selection: LVEF <50% (gemcitabine, doxorubicin contraindicated), CrCl <30 (methotrexate, lenalidomide dose constraints), bilirubin >3× ULN (brentuximab dose-modify Child-Pugh B; avoid C — limits ALCANZA option), or baseline peripheral neuropathy ≥grade 2 (brentuximab combination / vincristine prohibitive). |
|---|---|
| Direction clinique | désescalade |
| Catégorie | dysfonction d'organe |
Logique de déclenchement
{
"any_of": [
{
"comparator": "<",
"finding": "lvef_percent",
"threshold": 50
},
{
"comparator": "<",
"finding": "creatinine_clearance_ml_min",
"threshold": 30
},
{
"comparator": ">=",
"finding": "bilirubin_ratio_to_uln",
"threshold": 3
},
{
"finding": "child_pugh_class",
"value": "C"
},
{
"comparator": ">=",
"finding": "peripheral_neuropathy_grade",
"threshold": 2
}
],
"type": "lab_value"
}
Notes
MF/Sézary systemic options (mogamulizumab, brentuximab, romidepsin, bexarotene, IFN, low-dose MTX, gemcitabine, liposomal doxorubicin) span wide toxicity profiles — organ-dysfunction RF reroutes to better-tolerated agents. Mogamulizumab CCR4-targeted (MAVORIC) has minimal organ toxicity except infusion reactions / dermatitis — good organ-dysfunction-friendly choice. Bexarotene caution with hepatic / pancreatic dysfunction (hypertriglyceridemia / pancreatitis). Avoid vorinostat / romidepsin in significant renal/hepatic dysfunction.
Utilisé par
No reverse references found in the YAML corpus.